Real world evidence (RWE) is increasingly important in guiding reimbursement, but also treatment decisions, as HTAs, health insurers and clinicians are increasingly interested in the true real world (relative) effectiveness rather than the trials’ ideal (relative) efficacy. This requires combining and or comparing RWE effectiveness data with efficacy trial data. The primary aim of the study was to compare real world effectiveness with trial’s efficacy. Data from relevant 1st line MM RCTs were compared with corresponding treatment data in a Nordic RWE database of 3000 patients. The potential difference in response and overall survival (OS) was estimated by adjusting the RWE population to the RCT population, using matching adjusted indirect comparisons. Patients were matched on age, gender, calcium, beta2-microglobulin and ISS score. Surprisingly, our analyses showed that the matched median OS derived from the Nordic RWE database was very similar or even slightly better compared to the reported median OS in the trials. So the Nordic MM patients seem to do very well compared to, and even better than, patients treated in RCTs. This research is presented at European Hematology Association conference 2015.

If you are interested in a copy of the poster or in using matching adjusted indirect comparisons to bridge trial and RWE data, please contact Bart (Bart.Heeg@ingress-health.com) or Susanne (Susanne.Brandt@ingress-health.com).